Research Topics
| DEBORAH G GRADYSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A 60-year-old woman trying to discontinue hormone replacement therapyDeborah Grady
University of California, San Francisco, 74 New Montgomery St, Suite 600, San Francisco, CA 94105, USA
JAMA 287:2130-7. 2002- Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement StudyD Grady
University of California, San Francisco, San Francisco, California 94105, USA
Obstet Gynecol 97:116-20. 2001..To determine whether postmenopausal hormone therapy improves the severity of urinary incontinence... - Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluationDeborah Grady
University of California San Francisco, 1634 Divisadero Street, Suite 600, San Francisco, CA 94115, USA
Obstet Gynecol 104:837-44. 2004..To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen... - Predictors of difficulty when discontinuing postmenopausal hormone therapyDeborah Grady
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
Obstet Gynecol 102:1233-9. 2003..To describe the experiences of postmenopausal women who try to stop hormone therapy and to identify characteristics associated with inability to stop... - Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)Deborah Grady
Department of Epidemiology and Biostatistics, University of California, San Francisco, 74 New Montgomery St, Suite 600, San Francisco, CA 94105, USA
JAMA 288:49-57. 2002..However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5... - Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement StudyDeborah Grady
Department of Epidemiology and Biostatistics, University of California San Francisco, 1635 Divisidero Street, Suite 600, San Francisco, CA 94115, USA
Am J Med 113:543-8. 2002..To determine if hormone therapy results in better cognitive function in older postmenopausal women... - Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenElizabeth Barrett-Connor
Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093 0607, USA
N Engl J Med 355:125-37. 2006..The effect of raloxifene, a selective estrogen-receptor modulator, on coronary heart disease (CHD) and breast cancer is not established... 
Persistent hot flushes in older postmenopausal womenAlison J Huang
Department of Medicine, University of California San Francisco, USA
Arch Intern Med 168:840-6. 2008..To examine the prevalence, natural history, and predictors of hot flushes in older postmenopausal women...- The rise and fall of menopausal hormone therapyElizabeth Barrett-Connor
Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, 92093 0607, USA
Annu Rev Public Health 26:115-40. 2005..Differences between EPT and ET may reflect chance, baseline differences between the EPT and ET cohorts, or a progestin effect. Studies of younger women and lower HT doses with intermediate endpoints are beginning... - Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal womenDeborah Grady
University of California Women s Health Clinical Research Center, San Francisco, CA 94115, USA
Menopause 14:391-6. 2007..The purpose of this study was to determine whether 2 years of treatment with ultra-low-dose transdermal estradiol results in a change in breast density... 
Hot flushes, coronary heart disease, and hormone therapy in postmenopausal womenAlison J Huang
Departments of Medicine, University of California, San Francisco, CA 94115, USA
Menopause 16:639-43. 2009..The aim of this study was to examine interactions between hot flushes, estrogen plus progestogen therapy (EPT), and coronary heart disease (CHD) events in postmenopausal women with CHD...- Hot flushes, bone mineral density, and fractures in older postmenopausal womenAlison Huang
San Francisco Veterans Affairs Medical Center, University of California San Francisco, San Francisco, California 94121, USA
Obstet Gynecol 109:841-7. 2007..To assess whether greater severity of hot flushes is associated with bone loss or fracture risk in older postmenopausal women... - An intensive behavioral weight loss intervention and hot flushes in womenAlison J Huang
Department of Medicine, University of California, San Francisco, San Francisco, CA 94115, USA
Arch Intern Med 170:1161-7. 2010..Higher body mass index is associated with worse hot flushes during menopause but the effect of weight loss on flushing is unclear... - Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trialElizabeth Barrett-Connor
Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego School of Medicine, 9500 Gilman Dr, No 0607, La Jolla, CA 92093 0607, USA
JAMA 287:847-57. 2002..Raloxifene, a selective estrogen receptor modulator, improves cardiovascular risk factors, but its effect on cardiovascular events is unknown... - Postmenopausal hormones--therapy for symptoms onlyDeborah Grady
Department of Epidemiology and Biostatistics, University of California, San Francisco, and the San Francisco Veterans Affairs Medical Center, San Francisco, USA
N Engl J Med 348:1835-7. 2003 - Clinical trials in stem cell transplantation: guidelines for scientific and ethical reviewBernard Lo
Program in Medical Ethics and Department of Medicine, University of California, San Francisco, San Francisco, CA 94143 0903, USA
Clin Trials 5:517-22. 2008..Transplantation of cells derived through the manipulation of pluripotent stem cells may involve great uncertainty and the possibility of serious risks... - Restorative yoga in adults with metabolic syndrome: a randomized, controlled pilot trialBeth E Cohen
Department of General Internal Medicine, University of California, San Francisco, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
Metab Syndr Relat Disord 6:223-9. 2008..We conducted a randomized controlled pilot trial to determine whether a restorative yoga intervention was feasible and acceptable in underactive, overweight adults with metabolic syndrome... - The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinenceJeanette S Brown
University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, California 94115, USA
Ann Intern Med 144:715-23. 2006..Because treatments differ, urge incontinence should be distinguished from stress incontinence. To make this distinction, current guidelines recommend an extensive evaluation that is too time-consuming for primary care practice... - Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trialDeborah Grady
University of California, San Francisco, and San Francisco VA Medical Center, San Francisco, California 94115, USA
Obstet Gynecol 109:823-30. 2007..To estimate the effect of the selective serotonin reuptake inhibitor sertraline on hot flush frequency and severity in perimenopausal and postmenopausal women... - Oophorectomy as a risk factor for coronary heart diseaseVanessa L Jacoby
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, School of Medicine, San Francisco, CA 94115, USA
Am J Obstet Gynecol 200:140.e1-9. 2009..The objective of the study was to examine the relationship between bilateral oophorectomy (BSO) and risk of coronary heart disease (CHD)... - Weight loss to treat urinary incontinence in overweight and obese womenLeslee L Subak
University of California, San Francisco, San Francisco, USA
N Engl J Med 360:481-90. 2009..Obesity is an established and modifiable risk factor for urinary incontinence, but conclusive evidence for a beneficial effect of weight loss on urinary incontinence is lacking... - MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trialDeborah Grady
University of California, San Francisco, San Francisco, CA 94115, USA
Menopause 16:458-65. 2009..To determine the optimal dose, safety, and efficacy of an estrogen receptor beta selective Chinese herbal extract, menopausal formula 101 (MF101), for treating hot flushes... - Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary riskDeborah Grady
University of California, San Francisco, and San Francisco VA Medical Center, San Francisco, CA 94115, USA
J Natl Cancer Inst 100:854-61. 2008..Here, we provide further details about breast cancer incidence by tumor characteristics, duration of treatment, and subgroup... - Is a shorter hot flash diary just as good as a 7-day diary?Deborah Grady
University of California, San Francisco, CA 94115, USA
Menopause 16:932-6. 2009..Our objective was to determine if a shorter diary for recording self-reported hot flashes is as accurate and precise as the traditional 7-day diary... - Raloxifene and risk for stroke based on the framingham stroke risk scoreElizabeth Barrett-Connor
Division of Epidemiology, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, Calif 92093 0607, USA
Am J Med 122:754-61. 2009..We assessed whether this risk is concentrated in postmenopausal women already at high stroke risk... - Effect of Raloxifene on all-cause mortalityDeborah Grady
University of California, San Francisco, CA 94115, USA
Am J Med 123:469.e1-7. 2010..To assess the risk/benefit of raloxifene as a preventative treatment, we analyzed treatment effects on overall and cause-specific mortality... - Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational StudyVanessa L Jacoby
Departments of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA 94115, USA
Arch Intern Med 171:760-8. 2011..Elective bilateral salpingo-oophorectomy (BSO) is routinely performed with hysterectomy for benign conditions despite conflicting data on long-term outcomes... - Feasibility and acceptability of restorative yoga for treatment of hot flushes: a pilot trialBeth E Cohen
General Internal Medicine Section, San Francisco Veterans Affairs Medical Center, CA 94121 1598, USA
Maturitas 56:198-204. 2007..To determine the feasibility and acceptability of a restorative yoga intervention for the treatment of hot flushes in postmenopausal women... - Serum lipoprotein levels, statin use, and cognitive function in older womenKristine Yaffe
Departments of Psychiatry and Neurology, University of California, San Francisco, 4150 Clement St, Campus Box 111G, San Francisco, CA 94121, USA
Arch Neurol 59:378-84. 2002..Serum lipoprotein levels may be important predictors of cognitive function, and drugs that lower cholesterol may be effective for the prevention of cognitive impairment... - Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysisAlka M Kanaya
Department of Medicine, Division of General Internal Medicine, University of California, San Diego, USA
Arch Intern Med 162:1737-45. 2002..Most studies suggest that diabetes is a stronger coronary heart disease (CHD) risk factor for women than men, but few have adjusted their results for classic CHD risk factors: age, hypertension, total cholesterol level, and smoking... - Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trialAlka M Kanaya
Division of General Internal Medicine, University of California, San Francisco, 1701 Divisadero Street, Suite 536, San Francisco, CA 94143 1732, USA
Ann Intern Med 138:1-9. 2003..Randomized trials of postmenopausal hormone therapy have found differing effects on fasting glucose levels. No trial has evaluated the effect of hormone therapy on diabetes incidence... - Evaluation of abnormal mammography results and palpable breast abnormalitiesKarla Kerlikowske
University of California, San Francisco, General Internal Medicine Section, Department of Veterans Affairs, San Francisco, California 94121, USA
Ann Intern Med 139:274-84. 2003.... - Association of total and central obesity with mortality in postmenopausal women with coronary heart diseaseAlka M Kanaya
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 64115, USA
Am J Epidemiol 158:1161-70. 2003.... - Predictors of heart failure among women with coronary diseaseKirsten Bibbins-Domingo
Division of General Internal Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94143 1364, USA
Circulation 110:1424-30. 2004..We determined the risk factors for developing heart failure among postmenopausal women with established coronary disease... - Renal insufficiency as an independent predictor of mortality among women with heart failureKirsten Bibbins-Domingo
Division of General Internal Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, CA 94143 1364, USA
J Am Coll Cardiol 44:1593-600. 2004..We sought to explore the association between renal insufficiency and mortality among women with heart failure (HF) and to evaluate this risk by the presence of preserved or depressed systolic function... - Effect of hormone therapy on mortality rates among women with heart failure and coronary artery diseaseKirsten Bibbins-Domingo
Division of General Internal Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, CA 94143, USA
Am J Cardiol 95:289-91. 2005..Over the 4.1-year follow-up, estrogen plus progestin use had no effect on all-cause mortality (hazard ratio 1.0, 95% confidence interval 0.7 to 1.4, p = 0.8) in women with heart failure and coronary disease... - Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trialKristine Yaffe
Department of Psychiatry, University of California, San Francisco, Box 181, 4150 Clement St, San Francisco, CA 94121, USA
Am J Psychiatry 162:683-90. 2005..This investigation examined whether raloxifene, a selective estrogen receptor modulator, affects the risk for Alzheimer's disease... - Raloxifene and colorectal cancerJudith M E Walsh
Division of General Internal Medicine, University of California, San Francisco, USA
J Womens Health (Larchmt) 14:299-305. 2005..To determine the effect of raloxifene on colorectal cancer (CRC) risk... - Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of lifeKristine Yaffe
Department of Psychiatry, University of California, San Francisco, CA 94121, USA
Arch Neurol 63:945-50. 2006..The effect of an ultra-low- dose of unopposed transdermal estradiol on cognition and health-related quality of life is unknown... - Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)Stephen Hulley
Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, CA 94143 0560, USA
JAMA 288:58-66. 2002..The Heart and Estrogen/progestin Replacement Study (HERS) was a randomized trial of estrogen plus progestin therapy after menopause... - The "costs" of urinary incontinence for womenLeslee L Subak
Department of Obstetrics, Gynecology, University of California, San Francisco 94115, USA
Obstet Gynecol 107:908-16. 2006..To estimate costs of routine care for female urinary incontinence, health-related quality of life, and willingness to pay for incontinence improvement... - Discontinuation of postmenopausal hormone therapyDeborah Grady
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA
Am J Med 118:163-5. 2005..For women who cannot tolerate even a slow taper, the value of symptom relief likely outweighs any increased risks due to HT use... - Postmenopausal hormone therapy: does it cause incontinence?Jody E Steinauer
Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, 1001 Potrero Avenue, San Francisco, CA 94110, USA
Obstet Gynecol 106:940-5. 2005..To estimate the effect of hormone therapy on risk of stress and urge urinary incontinence... - The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal womenAlison Huang
Department of Medicine, University of California San Francisco School of Medicine, San Francisco, CA, USA
Am J Obstet Gynecol 198:265.e1-7. 2008..This study was undertaken to examine the effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women... - Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older womenKristine Yaffe
Department of Psychiatry, University of California San Francisco, Box 111G, 4150 Clement Street, San Francisco, CA 94121, USA
Biol Psychiatry 51:677-82. 2002..We investigated whether estrogen receptor 1 (ESR1) polymorphisms are associated with risk of developing cognitive impairment in older women... - Comparison of methods to measure low serum estradiol levels in postmenopausal womenJennifer S Lee
San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
J Clin Endocrinol Metab 91:3791-7. 2006..Accurate measurement of low serum estradiol (E(2) < 30 pg/ml or < 110 pmol/liter) is needed to study relationships between endogenous E(2) and risks of diseases in older women... - The day-to-day impact of urogenital aging: perspectives from racially/ethnically diverse womenAlison J Huang
Department of Medicine, University of California, San Francisco, CA, USA
J Gen Intern Med 25:45-51. 2010..Urogenital symptoms affect up to half of women after menopause, but their impact on women's day-to-day functioning and wellbeing is poorly understood... - Clinical practice. Management of menopausal symptomsDeborah Grady
Women's Health Clinical Research Center, University of California, San Francisco, CA 94115, USA
N Engl J Med 355:2338-47. 2006
Research Grants
- UCSF-KAISER WOMEN'S HEALTH INTERDISCIPLINARY SCHOLARSHIPDeborah Grady; Fiscal Year: 2004..Our goal is to create a model national resource for training successful investigators in women's health. ..
- PRIDE: Program to Reduce Incontinence by Diet & ExerciseDeborah Grady; Fiscal Year: 2007..CONSULTANT COSTS Delia Smith-West 5,500 EQUIPMENT (Itemize) Computers forTNB's (2,500 each) 5,000 SQL Server 7,500 12,500 SUPPLIES (Itemize by category) Project-related expenses 1,000 ' ^1000 TRAVEL 2 staff members to two ..
- PRIDE: Program to Reduce Incontinence by Diet & ExerciseLeslee Subak; Fiscal Year: 2007..abstract_text> ..